Harvard Bioscience (HBIO) Cash from Investing Activities Growth (1y) (2011 - 2026)
Harvard Bioscience (HBIO) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -528.34% |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -4.51% |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -4.35% |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -82.56% |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 40.11% |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | - |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -13.64% |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -420.31% |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -104.07% |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | 9.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.22% |
| Dec 31, 2025 | -28.54% |
| Sep 30, 2025 | 68.68% |
| Jun 30, 2025 | -150.87% |
| Mar 31, 2025 | -203.56% |
| Dec 31, 2024 | 56.08% |
| Sep 30, 2024 | -177.06% |
| Jun 30, 2024 | 173.28% |
| Mar 31, 2024 | -178.13% |
| Dec 31, 2023 | -351.49% |
| Sep 30, 2023 | 9.28% |
| Jun 30, 2023 | -41.40% |
| Mar 31, 2023 | 161.15% |
| Dec 31, 2022 | 34.36% |
| Sep 30, 2022 | 7.92% |
| Jun 30, 2022 | -114.56% |
| Mar 31, 2022 | -56.48% |
| Dec 31, 2021 | -14.01% |
| Sep 30, 2021 | 14.89% |
| Jun 30, 2021 | 27.21% |